{"id":921545,"date":"2025-12-19T11:01:10","date_gmt":"2025-12-19T16:01:10","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/"},"modified":"2025-12-19T11:01:10","modified_gmt":"2025-12-19T16:01:10","slug":"shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/","title":{"rendered":"Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\">MILWAUKEE<\/span>, <span class=\"legendSpanClass\">Dec. 19, 2025<\/span> \/PRNewswire\/ &#8212; The\u00a0Ademi Firm is investigating Amicus (Nasdaq: FOLD) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with BioMarin.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2672539\/Ademi_Fruchter__Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2672539\/Ademi_Fruchter__Logo.jpg\" title=\"Ademi &amp; Fruchter Logo (PRNewsfoto\/Ademi LLP)\" alt=\"Ademi &amp; Fruchter Logo (PRNewsfoto\/Ademi LLP)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Click <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4584592-1&amp;h=597894271&amp;u=https%3A%2F%2Fwww.ademilaw.com%2Fcase%2Famicus-therapeutics-inc%2F&amp;a=here\" target=\"_blank\" rel=\"nofollow\">here<\/a> to learn how to join our investigation and obtain additional information or contact us at <a href=\"mailto:gademi@ademilaw.com\" target=\"_blank\" rel=\"nofollow\">gademi@ademilaw.com<\/a> or toll-free: 866-264-3995.\u00a0 There is no cost or obligation to you.<\/p>\n<p>In the transaction, Amicus shareholders will receive $14.50 per share in an all-cash transaction valued at approximately $4.8 billion. Amicus insiders will receive substantial benefits as part of change of control arrangements.<\/p>\n<p>The transaction agreement unreasonably limits competing transactions for Amicus by imposing a significant penalty if Amicus accepts a competing bid. We are investigating the conduct of the Amicus board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.<\/p>\n<p>We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.<\/p>\n<p>Contacts<\/p>\n<p>Ademi &amp; Fruchter LLP\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <br \/>Guri Ademi<br \/>Toll Free: (866) 264-3995<br \/>Fax: (414) 482-8001<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=CG51679&amp;sd=2025-12-19\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders-302646931.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders-302646931.html<\/a><\/p>\n<p>SOURCE Ademi LLP<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CG51679&amp;Transmission_Id=202512191058PR_NEWS_USPR_____CG51679&amp;DateId=20251219\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire MILWAUKEE, Dec. 19, 2025 \/PRNewswire\/ &#8212; The\u00a0Ademi Firm is investigating Amicus (Nasdaq: FOLD) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with BioMarin. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.\u00a0 There is no cost or obligation to you. In the transaction, Amicus shareholders will receive $14.50 per share in an all-cash transaction valued at approximately $4.8 billion. Amicus insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Amicus by imposing a significant penalty if Amicus accepts a competing bid. We are investigating the conduct of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-921545","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire MILWAUKEE, Dec. 19, 2025 \/PRNewswire\/ &#8212; The\u00a0Ademi Firm is investigating Amicus (Nasdaq: FOLD) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with BioMarin. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.\u00a0 There is no cost or obligation to you. In the transaction, Amicus shareholders will receive $14.50 per share in an all-cash transaction valued at approximately $4.8 billion. Amicus insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Amicus by imposing a significant penalty if Amicus accepts a competing bid. We are investigating the conduct of &hellip; Continue reading &quot;Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-19T16:01:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2672539\/Ademi_Fruchter__Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders\",\"datePublished\":\"2025-12-19T16:01:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/\"},\"wordCount\":212,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2672539\\\/Ademi_Fruchter__Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/\",\"name\":\"Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2672539\\\/Ademi_Fruchter__Logo.jpg\",\"datePublished\":\"2025-12-19T16:01:10+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2672539\\\/Ademi_Fruchter__Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2672539\\\/Ademi_Fruchter__Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/","og_locale":"en_US","og_type":"article","og_title":"Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders - Market Newsdesk","og_description":"PR Newswire MILWAUKEE, Dec. 19, 2025 \/PRNewswire\/ &#8212; The\u00a0Ademi Firm is investigating Amicus (Nasdaq: FOLD) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with BioMarin. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.\u00a0 There is no cost or obligation to you. In the transaction, Amicus shareholders will receive $14.50 per share in an all-cash transaction valued at approximately $4.8 billion. Amicus insiders will receive substantial benefits as part of change of control arrangements. The transaction agreement unreasonably limits competing transactions for Amicus by imposing a significant penalty if Amicus accepts a competing bid. We are investigating the conduct of &hellip; Continue reading \"Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-19T16:01:10+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2672539\/Ademi_Fruchter__Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders","datePublished":"2025-12-19T16:01:10+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/"},"wordCount":212,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2672539\/Ademi_Fruchter__Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/","name":"Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2672539\/Ademi_Fruchter__Logo.jpg","datePublished":"2025-12-19T16:01:10+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2672539\/Ademi_Fruchter__Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2672539\/Ademi_Fruchter__Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-alert-the-ademi-firm-investigates-whether-amicus-therapeutics-inc-is-obtaining-a-fair-price-for-its-public-shareholders\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/921545","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=921545"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/921545\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=921545"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=921545"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=921545"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}